Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;33(2):153-158.
doi: 10.1007/s12288-017-0796-x. Epub 2017 Feb 28.

Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016

Nidhi Tandon  1 , Shaji K Kumar  1
Affiliations
Review

Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016

Nidhi Tandon et al. Indian J Hematol Blood Transfus. 2017 Jun.

Abstract

This review discusses the landmark studies in the field of multiple myeloma (MM) which were presented at American society of hematology annual meeting, 2016. There were contrary results from two large phase III trials (one from US and one from Europe) that evaluated the role of additional interventions like tandem autologous transplant (ASCT) and consolidation after induction therapy followed by ASCT in newly diagnosed MM (NDMM) patients, but there were critical differences between the two studies. Novel agents like carfilzomib and ixazomib proved to be of benefit when used as induction and post ASCT consolidation and maintenance in NDMM. The early data on subcutaneous administration of daratumumab (DARA) looked promising. The high rate of minimal residual disease negativity after using DARA even in relapsed/refractory MM (RRMM) setting reinforces the benefit of targeting CD38. The responses seen with venetoclax in RRMM with t(11;14)(high BCL-2, low BCL-XL and MCL-1) and selinexor in penta-refractory myeloma which fulfills the FDA category of unmet need, opens up newer options for these patients. BCMA CAR-T infusion shows encouraging results in advanced refractory myeloma patients.

Keywords: ASH annual meeting, 2016; Amyloidosis; Highlights; Multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

First Author—None. Corresponding Author—Celgene (Consultancy and Research Funding), Millennium (Consultancy and Research Funding), Novartis (Research Funding), Onyx (Consultancy and Research Funding), AbbVie (Research Funding), Janssen (Consultancy and Research Funding), BMS (Consultancy and Research Funding).

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

    1. Seckinger A, et al. Asymptomatic multiple myeloma—background of progression, evolution, and prognosis. Blood. 2016;128(22):235.
    1. Jackson GH, et al. Response adapted induction treatment improves outcomes for myeloma patients; results of the phase III myeloma XI study. Blood. 2016;128(22):244.
    1. Jackson GH, et al. Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the phase III myeloma XI study. Blood. 2016;128(22):1143.
    1. Stadtmauer EA, et al. Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with len maintenance (ACM), tandem autohct with len maintenance (TAM) and autohct with len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the blood and marrow transplant clinical trials network (BMT CTN 0702-StaMINA Trial) Blood. 2016;128(22):LBA-1.
    1. Cavo M, et al. Intensification therapy with bortezomib-melphalan-prednisone versus autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial) Blood. 2016;128(22):673.

LinkOut - more resources